It turned out that at optimal concentrations, both ASOs could effectively reduce the poly(GP) DPR level, without negatively impacting the Nop56 protein level in the fibroblasts and lymphoblastoid cell lines (LCLs) from SCA36 patients. This evidence concerns the gene NOP56 and spinocerebellar ataxia type 36.